The risk or severity of adverse effects can be increased when Cabergoline is combined with Metronidazole. The risk or severity of adverse effects can be increased when Metronidazole is combined with Ethanol. The metabolism of Metronidazole can be decreased when combined with Dosulepin. The risk or severity of adverse effects can be increased when Nicergoline is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Nilotinib. The metabolism of Metronidazole can be decreased when combined with Zafirlukast. The serum concentration of Bosutinib can be increased when it is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Tolbutamide. The metabolism of Metronidazole can be decreased when combined with Boceprevir. Metronidazole may increase the QTc-prolonging activities of Anagrelide. The serum concentration of Metronidazole can be decreased when it is combined with Siltuximab. The metabolism of Metronidazole can be decreased when combined with Fosamprenavir. The metabolism of Metronidazole can be decreased when combined with Crisaborole. The metabolism of Metronidazole can be increased when combined with Secobarbital. The metabolism of Metronidazole can be decreased when combined with Nelfinavir. The metabolism of Metronidazole can be decreased when combined with Abiraterone. Metronidazole may increase the QTc-prolonging activities of Citalopram. Metronidazole may increase the QTc-prolonging activities of Erythromycin. The metabolism of Metronidazole can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Ritonavir is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Sorafenib. The metabolism of Metronidazole can be decreased when combined with Gemfibrozil. The serum concentration of Metronidazole can be decreased when it is combined with Primidone. The serum concentration of Pitavastatin can be increased when it is combined with Metronidazole. The serum concentration of Metronidazole can be decreased when it is combined with St. John's Wort. The serum concentration of Metronidazole can be increased when it is combined with Dasatinib. The serum concentration of Amodiaquine can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Lumefantrine. The risk or severity of adverse effects can be increased when Metronidazole is combined with Disulfiram. The metabolism of Metronidazole can be decreased when combined with Amiodarone. Metronidazole may increase the QTc-prolonging activities of Tetrabenazine. The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Ziprasidone. The metabolism of Metronidazole can be decreased when combined with Clotrimazole. The serum concentration of Metronidazole can be decreased when it is combined with Deferasirox. The metabolism of Metronidazole can be decreased when combined with Isradipine. The metabolism of Metronidazole can be decreased when combined with Posaconazole. The metabolism of Metronidazole can be decreased when combined with Fluvoxamine. The metabolism of Metronidazole can be decreased when combined with Irbesartan. The metabolism of Metronidazole can be decreased when combined with Dihydroergotamine. The serum concentration of Metronidazole can be increased when it is combined with Stiripentol. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Clemastine. The metabolism of Metronidazole can be decreased when combined with Ticagrelor. The metabolism of Metronidazole can be decreased when combined with Atomoxetine. Metronidazole may increase the QTc-prolonging activities of Goserelin. The serum concentration of Fluindione can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Azithromycin. The metabolism of Metronidazole can be increased when combined with Pentobarbital. The metabolism of Metronidazole can be decreased when combined with Topiroxostat. The risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole. The metabolism of Metronidazole can be increased when combined with Nevirapine. The serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Metronidazole. The serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Metronidazole. The serum concentration of Metronidazole can be decreased when it is combined with Phenobarbital. The serum concentration of Conivaptan can be increased when it is combined with Metronidazole. The serum concentration of Metronidazole can be increased when it is combined with Fusidic Acid. The serum concentration of Metronidazole can be decreased when it is combined with Fosphenytoin. The serum concentration of Metronidazole can be increased when it is combined with Ceritinib. The serum concentration of Busulfan can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Flupentixol. The metabolism of Metronidazole can be decreased when combined with Efavirenz. Metronidazole may increase the QTc-prolonging activities of Asenapine. Metronidazole may increase the QTc-prolonging activities of Chloroquine. Metronidazole may increase the QTc-prolonging activities of Moxifloxacin. The serum concentration of Metronidazole can be increased when it is combined with Simeprevir. The metabolism of Metronidazole can be decreased when combined with Bortezomib. The serum concentration of Pravastatin can be increased when it is combined with Metronidazole. The serum concentration of Metronidazole can be increased when it is combined with Osimertinib. The metabolism of Metronidazole can be decreased when combined with Nicardipine. Metronidazole may increase the QTc-prolonging activities of Quinine. Metronidazole may increase the QTc-prolonging activities of Dofetilide. Metronidazole may increase the QTc-prolonging activities of Gadobenic acid. Metronidazole may increase the QTc-prolonging activities of Pimozide. The serum concentration of Metronidazole can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Pergolide is combined with Metronidazole. The serum concentration of Metronidazole can be increased when it is combined with Aprepitant. The metabolism of Metronidazole can be decreased when combined with Saquinavir. The metabolism of Metronidazole can be decreased when combined with Losartan. Metronidazole may increase the QTc-prolonging activities of Ondansetron. The metabolism of Metronidazole can be decreased when combined with Ranolazine. The metabolism of Metronidazole can be decreased when combined with Clarithromycin. Metronidazole may increase the QTc-prolonging activities of Fluoxetine. The serum concentration of Fluorouracil can be increased when it is combined with Metronidazole. The serum concentration of Metronidazole can be decreased when it is combined with Vemurafenib. The serum concentration of Phenindione can be increased when it is combined with Metronidazole. The metabolism of Metronidazole can be increased when combined with Rifampicin. Metronidazole may increase the QTc-prolonging activities of Propafenone. The serum concentration of Simvastatin can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Vandetanib. Metronidazole may increase the QTc-prolonging activities of Panobinostat. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Sotalol. Metronidazole may increase the QTc-prolonging activities of Escitalopram. Metronidazole may increase the QTc-prolonging activities of Ofloxacin. The metabolism of Metronidazole can be decreased when combined with Darunavir. The metabolism of Metronidazole can be decreased when combined with Pyrimethamine. The metabolism of Metronidazole can be decreased when combined with Rucaparib. Metronidazole may increase the QTc-prolonging activities of Methadone. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Voriconazole. The metabolism of Metronidazole can be decreased when combined with Omeprazole. The metabolism of Metronidazole can be decreased when combined with Cobicistat. Metronidazole may increase the QTc-prolonging activities of Dronedarone. The metabolism of Metronidazole can be increased when combined with Carbamazepine. The serum concentration of Metronidazole can be increased when it is combined with Luliconazole. The serum concentration of Mevastatin can be increased when it is combined with Metronidazole. The risk or severity of adverse effects can be increased when Ergonovine is combined with Metronidazole. The serum concentration of Metronidazole can be increased when it is combined with Fosaprepitant. The metabolism of Metronidazole can be decreased when combined with Lobeglitazone. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Telithromycin. Metronidazole may increase the QTc-prolonging activities of Telavancin. The serum concentration of Metronidazole can be increased when it is combined with Ivacaftor. The metabolism of Metronidazole can be decreased when combined with Olaparib. The metabolism of Metronidazole can be decreased when combined with Manidipine. Metronidazole may increase the QTc-prolonging activities of Granisetron. The metabolism of Metronidazole can be decreased when combined with Indinavir. The metabolism of Metronidazole can be decreased when combined with Fluvastatin. The metabolism of Metronidazole can be decreased when combined with Itraconazole. The metabolism of Metronidazole can be decreased when combined with Doxycycline. The metabolism of Metronidazole can be decreased when combined with Lovastatin. Metronidazole may increase the QTc-prolonging activities of Ciprofloxacin. The serum concentration of Warfarin can be increased when it is combined with Metronidazole. Metronidazole may increase the QTc-prolonging activities of Arsenic trioxide. The serum concentration of Metronidazole can be increased when it is combined with Palbociclib. The serum concentration of Ubidecarenone can be increased when it is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Floxuridine. The serum concentration of Ibrutinib can be increased when it is combined with Metronidazole. The metabolism of Metronidazole can be decreased when combined with Fluconazole.